Dulaglutide, the once weekly GLP-1R agonist continues to shine, while pipeline @LillyDiabetes continues to contain strong representation of GLP-1-related and novel peptide therapeutics #diabetespic.twitter.com/OrUzidRqAf
U tweetove putem weba ili aplikacija drugih proizvođača možete dodati podatke o lokaciji, kao što su grad ili točna lokacija. Povijest lokacija tweetova uvijek možete izbrisati. Saznajte više
Dulaglutide, the once weekly GLP-1R agonist continues to shine, while pipeline @LillyDiabetes continues to contain strong representation of GLP-1-related and novel peptide therapeutics #diabetespic.twitter.com/OrUzidRqAf
The future #T2D #obesity #NASH @LillyPad has rolled the dice on the titan GLP-1-GIP twincretin Tirzepatide, first P3 #T2D trials reporting in 2020, H2H CVOT vs. dulaglutide recruiting https://investor.lilly.com/static-files/6eac06d9-1beb-466a-8e5a-11a1911b8d36 …pic.twitter.com/yqduM9pK1V
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.